医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Avita Medical Names Erin Liberto as Chief Commercial Officer

2017年08月31日 AM08:27
このエントリーをはてなブックマークに追加


 

VALENCIA, Calif. & PERTH, Australia & LONDON

Avita Medical, Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company developing innovative therapeutic solutions derived from the regenerative properties of a patient’s own skin, today announced that Erin Liberto has become the company’s Chief Commercial Officer effective 28 August 2017.

As CCO of Avita Medical, Ms. Liberto will have responsibility for successful execution of the company’s comprehensive commercial strategy including the further development of the company’s sales, reimbursement and marketing efforts, and will report directly to Chief Executive Officer Dr. Michael Perry.

“Erin’s extensive experience in the global dermatology markets, including a proven track record of successful US product launches, will be instrumental as we position ReCell® in the US burns market following our anticipated PMA approval next year,” said Dr. Perry. “We are laying the foundation for our future growth across multiple indications, and I’m energized to be working with Erin as we continue to leverage our clinical progress across a broad range of indications.”

Ms. Liberto was most recently Vice President of Marketing, Topical Dermatology at Allergan (NYSE: AGN) where she led the commercial operations of marketing and strategic communication for two dermatology franchises: SkinMedica®, a cash-pay, physician dispensed topical aesthetics business unit, and the Medical Dermatology division which included reimbursed topical pharmaceutical products for skin conditions and where she oversaw more than US$650M of business revenue. While at Allergan, she doubled the domestic SkinMedica® growth rate; gained the #1 share position for the therapeutic acne product Aczone®; launched the new 7.5% Aczone® formulation in mid-2016, and achieved the most successful launch in the professional dispensed skin care market. Previously, (2001-2007) Erin served as Director of US Marketing at Biosense Webster, a division of Johnson & Johnson (NYSE: JNJ).

ABOUT AVITA MEDICAL LIMITED

Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. Our medical devices work by preparing a Regenerative Epithelial Suspension (RES™), an autologous suspension comprised of the patients’ own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This is then applied to the area to be treated.

In all countries outside of Europe, our portfolio is marketed under the ReCell® brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics.

ReCell® is TGA‐registered in Australia, and CFDA‐cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use.

In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. ReCell® is designed for the treatment of burns and plastic reconstructive procedures; ReGenerCell™ has been formulated for chronic wounds including leg and foot ulcers; and ReNovaCell™ is tailored for aesthetic applications including the restoration of pigmentation.

To learn more, visit www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170830006317/en/

CONTACT

Australia
Monsoon Communications
Sarah Kemter
Phone:
+61 (0)3 9620 3333
Mobile: +61 (0)407 162 530
sarahk@monsoon.com.au
or
USA
Westwicke
Partners

Jamar Ismail
Phone +1 (415) 513-1282
jamar.ismail@westwicke.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CDISC and Cohen Veterans Bioscience Announce Public Review for Post Traumatic Stress Disorder Therapeutic Area User Guide
  • New Data on Automotive, Consumer Health and Consumer Finance from Euromonitor
  • 第6回年次世界患者安全・科学・技術サミットを英国ロンドンで開催へ
  • Sun Pharma Odomzo® (Sonidegib) New Label Approval Shows Sustained Duration of Response of 26 Months in Treatment of Locally Advanced Basal Cell Carcinoma
  • Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited